View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 22, 2021updated 12 Jul 2022 11:18am

Valneva begins Phase III trial of Covid-19 vaccine candidate in UK 

Valneva has started a pivotal Phase III Cov-Compare (VLA2001-301) clinical trial of its inactivated, Covid-19 vaccine candidate, VLA2001.

Valneva has started a pivotal Phase III Cov-Compare (VLA2001-301) clinical trial of its inactivated, Covid-19 vaccine candidate, VLA2001.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

VLA2001 has inactivated whole virus particles of SARS-CoV-2 with high S-protein density and two adjuvants, alum and Dynavax’s CpG 1018.

The latest development follows positive initial data from Valneva’s Phase I/II clinical trial that showed the vaccine’s safety profile and immunogenicity.

Cov-Compare will analyse VLA2001 as compared with AstraZeneca’s conditionally approved vaccine Vaxzevria.

This randomised, observer-blind, controlled, comparative immunogenicity trial will enrol around 4,000 adult participants. Supported by the UK National Institute for Health Research, the trial will be carried out at approximately 25 sites in the UK.

The participants will receive two intramuscular doses of the vaccine administered four weeks apart.

Its primary objective is to establish the superiority of VLA2001 over Vaxzevria in terms of Geometric Mean Titer ratio of SARS-CoV-2-specific neutralising antibodies in adult subjects aged 30 years and above, at two weeks on administering the second dose.

In addition, the trial will assess the safety and tolerability of the vaccine at two weeks after administering the second dose in adult subjects aged 18 and above.

On obtaining promising data from this trial, Valneva plans to submit an application to obtain initial regulatory approval for the vaccine in September this year.

Dynavax CEO Ryan Spencer said: “We are excited to see the rapid initiation of the comparative Phase III clinical trial, providing an opportunity for Valneva’s inactivated whole virus vaccine candidate adjuvanted with CpG 1018 to demonstrate superior immunogenicity with respect to the comparator.”

Valneva commenced the Phase I/II VLA2001-201 clinical study of VLA2001 in December last year.

In another development, Claritas Pharmaceuticals and CMAX Clinical Research have entered into an agreement to carry out a Phase I clinical study of the former’s novel, liquid, nitric oxide-releasing drug R-107 for Covid-19 treatment.

The randomised, placebo-controlled, single-blind, single ascending dose trial will analyse the pharmacokinetics and safety profile of R-107.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena